CarcinomaPhase 2NCT05913661
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
A Phase 2 study testing Pemigatinib and PD-1 Inhibitors in people with Carcinoma and Intrahepatic Cholangiocarcinoma, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms
- What is being tested?
- Pemigatinib and PD-1 Inhibitors
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- Jul 2023to Nov 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Local advanced, recurrent, or metastatic cholangiocarcinoma confirmed by histology or cytology and judged as unresectable by imaging and clinical diagnosis;
- Have not received systematic treatment in the past;
- The existence of FGFR2 fusion/rearrangement was confirmed by gene detection;
- Male or female aged ≥ 18 years;
- According to RECIST v1.1, there is at least one measurable target lesion. And the target lesion has not received local treatment;
- No other anti-tumor treatment was received within 4 weeks before the first use of the study drug;
Show all 10Show fewer
- Life expectancy ≥ 12 weeks;
- Eastern Oncology Collaboration group (ECOG) physical condition (PS) score 0-1;
- Having sufficient organ and bone marrow function reserve, which is defined as follows:(1)Absolute neutrophil count (ANC) ≥ 1.5 × 109/L Platelet count (PLT) ≥ 80 × 109/L Hemoglobin content (HGB) ≥ 9.0 g/dL. G-CSF, GM-CSF, red blood cell infusion, and platelet infusion were not used within 14 days before the examination; (2)Liver function requirement for patients without liver metastasis: serum total bilirubin (TBIL) ≤ 1.5 × Upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Requirements for patients with liver metastasis or intrahepatic cholangiocarcinoma: serum TBIL ≤ 1.5 × ULN; ALT and AST ≤ 5 × ULN; (3)Renal function: creatinine clearance rate (Ccr) ≥ 50 mL/min (calculated by Cockcroft/Default formula): female: CrCl=(0.85 × (140 - Age) × (Weight)/(72 × Serum creatinine (mg/dL), male: CrCl=(140 age) × (Weight)/(72 × Serum creatinine (mg/dL); (4)Sufficient blood coagulation function, defined as the international standardized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; If the subject is receiving anticoagulation treatment, it is acceptable as long as PT is within the scope of anticoagulation drugs;
- Female subjects of reproductive age or male subjects with female sexual partners of reproductive age shall take effective contraceptive measures during the whole treatment period and 6 months after the treatment period.
Who cannot join
- Previously received selective FGFR inhibitor treatment, excluding pan target inhibitors such as Anlotinib and Lenvatinib
- Received immunosuppressive drugs within 4 weeks before the first administration of the trial treatment, excluding local glucocorticoids or systemic glucocorticoids of physiological dose by nasal spray, inhalation, or other means (i.e. no more than 10 mg/day prednisone or other glucocorticoids of equivalent dose).
- Received live attenuated vaccine within 4 weeks before the first administration of the trial treatment or during the study period.
- Received any other study drug treatment or participated in interventional clinical research 4 weeks before the first administration of the trial treatment;
- Before the first administration of the trial treatment, there was toxicity caused by previous anti-tumor treatment that was not restored to the level 0 or 1 of the National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 (NCI CTCAE Version 5.0) (excluding alopecia, non-clinically significant laboratory abnormalities, and asymptomatic laboratory abnormalities).
- Active, known or suspected autoimmune disease, or history of autoimmune disease in the past 2 years (patients with vitiligo that do not need systematic treatment, psoriasis, alopecia, or Graves' disease in the past 2 years, hypothyroidism who only need thyroid hormone replacement therapy and type I diabetes who only need insulin replacement therapy can be enrolled).
Show all 36Show fewer
- Known history of primary immunodeficiency.
- Known to have active pulmonary tuberculosis.
- Known Symptomatic central nervous system metastases and/or carcinomatous meningitis. For patients with brain metastasis who have received treatment in the past, if their condition is stable (no evidence of imaging progress is found at least 4 weeks before the first administration of the trial treatment), and repeated imaging examination proves that there is no evidence of new brain metastasis or enlargement of the original brain metastasis focus, and they do not need steroid treatment at least 14 days before the first administration of the trial treatment, they can participate in the trial. This exception does not include carcinomatous meningitis, regardless of its clinical stability should be excluded.
- Medical history of other primary malignant tumors, except: (1)malignant tumors that have completely alleviated for at least 5 years before enrollment and do not require other treatment during the study period; (2)Fully treated non-melanoma skin cancer or malignant lentigo without evidence of disease recurrence; (3)Fully treated carcinoma in situ without evidence of disease recurrence.
- During pregnancy or lactation.
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- The following abnormal laboratory parameters: (1) Serum phosphate > ULN, and considered clinically significant by the investigator; (2) Serum calcium > ULN, or when serum albumin exceeds the normal range, the corrected calcium concentration of serum albumin exceeds the normal upper limit.
- Known history of human immunodeficiency virus (HIV) infection or confirmed positive immune test result.
- Known active serious infections or poorly clinically controlled infections.
- Pleural fluid, ascites, or pericardial effusion with obvious clinical symptoms and requiring drainage.
- Patients with acute or chronic active hepatitis B or hepatitis C, whose hepatitis B virus (HBV) DNA>2000 IU/ml or 10^4 copies/ml, or Hepatitis C virus (HCV) RNA>10^3 copies/ml, or Hepatitis B surface antigen (HBsAg) and anti HCV antibody were both positive. If laboratory parameters can be reduced to lower than the above standards after nucleotides antiviral treatment, the patient can be enrolled.
- Clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first administration of the trial treatment, New York Heart Association(NYHA) III/IV congestive heart failure, and uncontrolled arrhythmia (subjects with a pacemaker or atrial fibrillation with well-controlled heart rate can be enrolled).
- There are ECG changes or medical history that the researchers consider clinically significant; For screening subjects with QTcF interval>480 ms and indoor conduction block (QRS interval>120 ms), JTc interval can be used to replace QTc interval after being approved by the sponsor (if so, JTc must be ≤ 340 ms).
- Uncontrolled hypertension, systolic pressure>160 mmHg or diastolic pressure>100 mmHg after optimal medical treatment, hypertension crisis, or hypertensive encephalopathy history.
- Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh B or more severe cirrhosis.
- Patients with interstitial lung disease.
- Major surgery (craniotomy, thoracotomy, or laparotomy) was performed within 4 weeks before the first administration of the trial treatment, or major surgery was expected to be performed during the study treatment.
- Before starting treatment, the toxicity and/or complications of major surgery have not been fully recovered.
- Pregnant or lactating females, or subjects who are expected to be pregnant or give birth during the study period from the screening follow-up to the completion of the safety follow-up (male subjects to 90 days after the last administration of the trial treatment).
- Received radiotherapy within 4 weeks before the first administration of the trial treatment. The radiotherapy-related toxicity of the subject must have been fully recovered, and no corticosteroid treatment is required. It is confirmed that radiation pneumonia is excluded. For palliative radiotherapy for non-CNS diseases, a 2-week washout period is allowed.
- History of disorder of calcium and phosphorus metabolism, or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidney, tendon, or blood vessel without systemic electrolyte metabolism imbalance caused by injury, disease, advanced age, and other reasons).
- Corneal or retinal diseases with clinical significance confirmed by ophthalmological examination.
- Received any potent CYP3A4 inhibitor or inducer was used 14 days or within 5 half-lives (whichever is shorter) before the first administration of the trial treatment. Ketoconazole is allowed for external use.
- Known allergic reaction to pemigatinib or the excipients of the study drug pemigatinib.
- Known hypersensitivity to any monoclonal antibody.
- The investigator considered that the subject could not comply with the administration arrangement and study evaluation.
- Unable to understand or unwilling to sign the Informed Consent Form (ICF).
- Unable or unwilling to swallow pemigatinib or suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion.
- Known history of vitamin D deficiency and needed to supplement vitamin D beyond the physiological dosage (except for vitamin D dietary supplements).
- Other acute or chronic diseases, mental diseases, or abnormal laboratory parameters that may lead to the following results: increase the risk related to the study participation or study drug administration, or interfere with the interpretation of the study results, and the patient is listed as ineligible to participate in the study according to the judgment of the investigator.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Lei Zhang
Guangzhou, Guangdong, 510220
Lei Zhang, PHD, +8613602730646, zhangl9@mail.sysu.edu.cn
About this study
Official title: Prospective, Single-arm, Multicenter Phase II Study of Evaluation of the Efficacy and Safety of Pemigatinib Combined With PD-1 Inhibitor in First-line Treatment of Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma.
Read the detailed description
The study will be divided into two phases. The first phase is the safety import phase, in which three subjects with intrahepatic cholangiocarcinoma will be enrolled to receive a Scheduled dose of pemigatinib for one course of treatment， If the initial three subjects didn't develop DLT during the 21-day observation period, the dose will be considered tolerable and the study will proceed to Part II, otherwise, the dose will be adjusted and the evaluation will continue according to the above criteria.
A total of 30 subjects will be enrolled in Phase II of the study, and all screening-qualified subjects will receive pemigatinib combined with PD-1 inhibitor. pemigatinib and PD-1 inhibitors will be administered at established doses according to a regimen until progressive disease, intolerable toxicity, or informed consent form has been withdrawn. PD-1 inhibitors will be administered for a maximum of 24 months.
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor, First-line Treatment
- Being tested
- Pemigatinib, PD-1 Inhibitors
- Keywords
- unresectable intrahepatic cholangiocarcinoma, metastatic intrahepatic cholangiocarcinoma, first-line treatment, Pemigatinib, PD-1 inhibitor
- Medical subject headings
- Carcinoma, Cholangiocarcinoma, Digestive System Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PemigatinibDrug
Also called Pemazyre
Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
PD-1 InhibitorsDrug
Also called Sintilimab
The dosing regimen is 200 mg IV Q3W
| Study group | Role | What they receive |
|---|---|---|
| pemigatinib combined with PD-1 inhibitor | Experimental | pemigatinib combined with PD-1 inhibitor as first-line treatment within advanced unresectable or metastatic intrahepatic cholangiocarcinoma Receives: Drug: Pemigatinib; Drug: PD-1 Inhibitors |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate
The proportion of subjects who achieved complete response (CR; all target lesions disappeared) or partial response (PR; the sum of the longest diameter of target lesions decreased by ≥ 30%) according to the RECIST1.1 standard.
Measured: 2 years
Secondary outcomes (4)
Progression-Free-Survival
From the first administration to progressive disease[PD] or death.
Measured: 2 years
Duration of Response
the period of time from the days which achieved complete response[CR] or partial response[PR] to progressive disease[PD]. This outcome measure is only applied to the subjects with objective remission
Measured: 2 years
Disease Control Rate
The proportion of the sum of complete response[CR]、partial response[PR]、stable disease[SD] among the total cases.
Measured: 2 years
Overall Survival
from the date of enrollment to Death
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2023
- Study startJul 2023 (estimated)
- Primary completionNov 2024 (estimated)
- Study completionNov 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CarcinomaStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- First Affiliated Hospital of Jinan University, Shenzhen University General Hospital
- Responsible party
- Sponsor
- Investigators
- Lei Zhang, PHD, Principal investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05913661
- Sponsor's protocol ID
- SYSKY-2023-061-01
- Status last verified
- Feb 2023
- First submitted
- 5 Jun 2023
- Last updated
- 22 Jun 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Single-arm, Multicenter Phase II Study of Evaluation of the Efficacy and Safety of Pemigatinib Combined With PD-1 Inhibitor in First-line Treatment of Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- ClinicalTrials.gov ID
- NCT05913661
- Acronym / sponsor ID
- SYSKY-2023-061-01
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor, First-line Treatment
- Keywords
- unresectable intrahepatic cholangiocarcinoma, metastatic intrahepatic cholangiocarcinoma, first-line treatment, Pemigatinib, PD-1 inhibitor
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Collaborators
- First Affiliated Hospital of Jinan University, Shenzhen University General Hospital
- Study start
- Jul 2023 (estimated)
- Primary completion
- Nov 2024 (estimated)
- Study completion
- Nov 2024 (estimated)
- First posted
- 22 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma.
Detailed description
The study will be divided into two phases. The first phase is the safety import phase, in which three subjects with intrahepatic cholangiocarcinoma will be enrolled to receive a Scheduled dose of pemigatinib for one course of treatment， If the initial three subjects didn't develop DLT during the 21-day observation period, the dose will be considered tolerable and the study will proceed to Part II, otherwise, the dose will be adjusted and the evaluation will continue according to the above criteria.
A total of 30 subjects will be enrolled in Phase II of the study, and all screening-qualified subjects will receive pemigatinib combined with PD-1 inhibitor. pemigatinib and PD-1 inhibitors will be administered at established doses according to a regimen until progressive disease, intolerable toxicity, or informed consent form has been withdrawn. PD-1 inhibitors will be administered for a maximum of 24 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pemigatinib combined with PD-1 inhibitor | Experimental | Drug: Pemigatinib, Drug: PD-1 Inhibitorspemigatinib combined with PD-1 inhibitor as first-line treatment within advanced unresectable or metastatic intrahepatic cholangiocarcinoma |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Local advanced, recurrent, or metastatic cholangiocarcinoma confirmed by histology or cytology and judged as unresectable by imaging and clinical diagnosis;
- Have not received systematic treatment in the past;
- The existence of FGFR2 fusion/rearrangement was confirmed by gene detection;
- Male or female aged ≥ 18 years;
- According to RECIST v1.1, there is at least one measurable target lesion. And the target lesion has not received local treatment;
Key exclusion criteria (36 listed)
- Previously received selective FGFR inhibitor treatment, excluding pan target inhibitors such as Anlotinib and Lenvatinib
- Received immunosuppressive drugs within 4 weeks before the first administration of the trial treatment, excluding local glucocorticoids or systemic glucocorticoids of physiological dose by nasal spray, inhalation, or other means (i.e. no more than 10 mg/day prednisone or other glucocorticoids of equivalent dose).
- Received live attenuated vaccine within 4 weeks before the first administration of the trial treatment or during the study period.
- Received any other study drug treatment or participated in interventional clinical research 4 weeks before the first administration of the trial treatment;
- Before the first administration of the trial treatment, there was toxicity caused by previous anti-tumor treatment that was not restored to the level 0 or 1 of the National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 (NCI CTCAE Version 5.0) (excluding alopecia, non-clinically significant laboratory abnormalities, and asymptomatic laboratory abnormalities).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PemigatinibAlso: PemazyrePemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen. | Drug | pemigatinib combined with PD-1 inhibitor |
| PD-1 InhibitorsAlso: SintilimabThe dosing regimen is 200 mg IV Q3W | Drug | pemigatinib combined with PD-1 inhibitor |
Primary outcome
Objective Response Rate
Time frame: 2 years
The proportion of subjects who achieved complete response (CR; all target lesions disappeared) or partial response (PR; the sum of the longest diameter of target lesions decreased by ≥ 30%) according to the RECIST1.1 standard.
4 secondary outcomes
Progression-Free-Survival
Time frame: 2 years
Duration of Response
Time frame: 2 years
Disease Control Rate
Time frame: 2 years
Overall Survival
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2023.
- Individual participant dataSharing planned: No
Related trials for Carcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lei Zhang, PHD principal investigator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pemigatinib and PD-1 Inhibitors in people with Carcinoma and Intrahepatic Cholangiocarcinoma, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Lei Zhang, PHD (86-136-0273-0646, zhangl9@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2023.